Released Nov 10, 2025, after the close
10-Q filed Nov 10, 2025, 41 days after period end · 0001193125-25-274277
Q3 2025 · 10-Q
Revenue$10.79M$10.79M +57.6% vs Q3 2024+12.1% vs Q2 2025
Net Income-$9.20M-$9.20M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.72-$0.72 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$10,883,000N/M
Operating Cash Flowderived-$15,133,000N/M
Free Cash Flowderived-$15,175,000N/M
Margins · derived
Operating margin-100.9%+59.2 pt vs Q3 2024
Net margin-85.2%+55.2 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $10.79M | $6.85M | $0.00 | — |
| Net Income | -$9.20M | -$9.61M | -$14.42M | -$23.15M |
| EPS Diluted | -$0.72 | -$1.51 | -$3.29 | -$0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR